-
1
-
-
60849108332
-
Multiple myeloma
-
Rajkumar SV. Multiple myeloma. Curr Probl Cancer. 2009;33(1):7-64.
-
(2009)
Curr Probl Cancer
, vol.33
, Issue.1
, pp. 7-64
-
-
Rajkumar, S.V.1
-
2
-
-
74049142026
-
The use of novel agents in the treatment of relapsed and refractory multiple myeloma
-
Laubach JP, Mahindra A, Mitsiades CS, Schlossman RL, Munshi NC, Ghobrial IM, et al. The use of novel agents in the treatment of relapsed and refractory multiple myeloma. Leukemia. 2009;23(12):2222-32.
-
(2009)
Leukemia
, vol.23
, Issue.12
, pp. 2222-2232
-
-
Laubach, J.P.1
Mahindra, A.2
Mitsiades, C.S.3
Schlossman, R.L.4
Munshi, N.C.5
Ghobrial, I.M.6
-
3
-
-
77949429892
-
Novel therapeutic targets for multiple myeloma
-
Mahindra A, Cirstea D, Raje N. Novel therapeutic targets for multiple myeloma. Future Oncol. 2010;6(3):407-18.
-
(2010)
Future Oncol
, vol.6
, Issue.3
, pp. 407-418
-
-
Mahindra, A.1
Cirstea, D.2
Raje, N.3
-
4
-
-
84862658798
-
Relapsed/refractory multiple myeloma: defining refractory disease and identifying strategies to overcome resistance
-
Siegel DS. Relapsed/refractory multiple myeloma: defining refractory disease and identifying strategies to overcome resistance. Semin Hematol. 2012;49(Suppl 1):S3-15.
-
(2012)
Semin Hematol
, vol.49
, pp. S3-S15
-
-
Siegel, D.S.1
-
5
-
-
58249101211
-
Bone marrow microenvironment and the identification of new targets for myeloma therapy
-
Podar K, Chauhan D, Anderson KC. Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia. 2009;23(1):10-24.
-
(2009)
Leukemia
, vol.23
, Issue.1
, pp. 10-24
-
-
Podar, K.1
Chauhan, D.2
Anderson, K.C.3
-
6
-
-
79953647466
-
The Syk kinase as a therapeutic target in leukemia and lymphoma
-
Efremov DG, Laurenti L. The Syk kinase as a therapeutic target in leukemia and lymphoma. Expert Opin Investig Drugs. 2011;20(5):623-36.
-
(2011)
Expert Opin Investig Drugs.
, vol.20
, Issue.5
, pp. 623-636
-
-
Efremov, D.G.1
Laurenti, L.2
-
7
-
-
33646492861
-
Cutting edge: constitutive B cell receptor signalling is critical for basal growth of B lymphoma
-
Gururajan M, Jennings CD, Bondada S. Cutting edge: constitutive B cell receptor signalling is critical for basal growth of B lymphoma. J Immunol. 2006;176:5715-9.
-
(2006)
J Immunol.
, vol.176
, pp. 5715-5719
-
-
Gururajan, M.1
Jennings, C.D.2
Bondada, S.3
-
8
-
-
77649250977
-
STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress
-
Uckun FM, Qazi S, Ma H, Tuel-Ahlgren L, Ozer Z. STAT3 is a substrate of SYK tyrosine kinase in B-lineage leukemia/lymphoma cells exposed to oxidative stress. Proc Natl Acad Sci USA. 2010;107(7):2902-7.
-
(2010)
Proc Natl Acad Sci USA
, vol.107
, Issue.7
, pp. 2902-2907
-
-
Uckun, F.M.1
Qazi, S.2
Ma, H.3
Tuel-Ahlgren, L.4
Ozer, Z.5
-
9
-
-
3242777803
-
Advances in biology of multiple myeloma: clinical applications
-
Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood. 2004;104(3):607-18.
-
(2004)
Blood
, vol.104
, Issue.3
, pp. 607-618
-
-
Hideshima, T.1
Bergsagel, P.L.2
Kuehl, W.M.3
Anderson, K.C.4
-
11
-
-
77952887713
-
The SYK tyrosine kinase: a crucial player in diverse biological functions
-
Mocsai A, Ruland J, Tybulewicz VL. The SYK tyrosine kinase: a crucial player in diverse biological functions. Nat Rev Immunol. 2010;10(6):387-402.
-
(2010)
Nat Rev Immunol
, vol.10
, Issue.6
, pp. 387-402
-
-
Mocsai, A.1
Ruland, J.2
Tybulewicz, V.L.3
-
12
-
-
79955965433
-
Priming of the vascular endothelial growth factor signalling pathway by thrombospondin-1, CD36, and spleen tyrosine kinase
-
Kazerounian S, Duquette M, Reyes MA, Lawler JT, Song K, Perruzzi C, et al. Priming of the vascular endothelial growth factor signalling pathway by thrombospondin-1, CD36, and spleen tyrosine kinase. Blood. 2011;117(17):4658-66.
-
(2011)
Blood
, vol.117
, Issue.17
, pp. 4658-4666
-
-
Kazerounian, S.1
Duquette, M.2
Reyes, M.A.3
Lawler, J.T.4
Song, K.5
Perruzzi, C.6
-
13
-
-
79955449327
-
Syk regulates multiple signaling pathways leading to CX3CL1 chemotaxis in macrophages
-
Park H, Cox D. Syk regulates multiple signaling pathways leading to CX3CL1 chemotaxis in macrophages. J Biol Chem. 2011;286(17):14762-9.
-
(2011)
J Biol Chem
, vol.286
, Issue.17
, pp. 14762-14769
-
-
Park, H.1
Cox, D.2
-
14
-
-
67649425382
-
Syk and pTyr'd: signaling through the B cell antigen receptor
-
Geahlen RL. Syk and pTyr'd: signaling through the B cell antigen receptor. Biochim Biophys Acta. 2009;1793(7):1115-27.
-
(2009)
Biochim Biophys Acta
, vol.1793
, Issue.7
, pp. 1115-1127
-
-
Geahlen, R.L.1
-
15
-
-
0033997615
-
Tyrosine kinase SYK: essential functions for immunoreceptor signalling
-
Turner M, Schweighoffer E, Colucci F, Di Santo JP, Tybulewicz VL. Tyrosine kinase SYK: essential functions for immunoreceptor signalling. Immunol Today. 2000;21:148-54.
-
(2000)
Immunol Today
, vol.21
, pp. 148-154
-
-
Turner, M.1
Schweighoffer, E.2
Colucci, F.3
Santo, J.P.4
Tybulewicz, V.L.5
-
16
-
-
0030898417
-
Mitogen-activated protein kinase pathways
-
Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol. 1997;9(2):180-6.
-
(1997)
Curr Opin Cell Biol
, vol.9
, Issue.2
, pp. 180-186
-
-
Robinson, M.J.1
Cobb, M.H.2
-
17
-
-
0347482409
-
B cell antigen-receptor signalling in lymphocyte development
-
Wang LD, Clark MR. B cell antigen-receptor signalling in lymphocyte development. Immunology. 2003;110(4):411-20.
-
(2003)
Immunology
, vol.110
, Issue.4
, pp. 411-420
-
-
Wang, L.D.1
Clark, M.R.2
-
18
-
-
34249105476
-
Structural basis for the inhibition of tyrosine kinase activity of ZAP-70
-
Deindl S, Kadlecek TA, Brdicka T, Cao X, Weiss A, Kuriyan J. Structural basis for the inhibition of tyrosine kinase activity of ZAP-70. Cell. 2007;129:735-46.
-
(2007)
Cell
, vol.129
, pp. 735-746
-
-
Deindl, S.1
Kadlecek, T.A.2
Brdicka, T.3
Cao, X.4
Weiss, A.5
Kuriyan, J.6
-
19
-
-
0034874786
-
Structure and function of Syk protein-tyrosine kinase
-
Sada K, Takano T, Yanagi S, Yamamura H. Structure and function of Syk protein-tyrosine kinase. J Biochem. 2001;130(2):177-86.
-
(2001)
J Biochem
, vol.130
, Issue.2
, pp. 177-186
-
-
Sada, K.1
Takano, T.2
Yanagi, S.3
Yamamura, H.4
-
20
-
-
0028889302
-
Perinatal lethality and blocked B cell development in mice lacking the tyrosine kinase Syk
-
Turner M, Mee PJ, Costello PS, Williams O, Price AA, Duddy LP, et al. Perinatal lethality and blocked B cell development in mice lacking the tyrosine kinase Syk. Nature. 1995;378:298-302.
-
(1995)
Nature
, vol.378
, pp. 298-302
-
-
Turner, M.1
Mee, P.J.2
Costello, P.S.3
Williams, O.4
Price, A.A.5
Duddy, L.P.6
-
21
-
-
0028783322
-
Syk tyrosine kinase required for mouse viability and B cell development
-
Cheng AM, Rowley B, Pao W, Hayday A, Bolen JB, Pawson T. Syk tyrosine kinase required for mouse viability and B cell development. Nature. 1995;378:303-6.
-
(1995)
Nature
, vol.378
, pp. 303-306
-
-
Cheng, A.M.1
Rowley, B.2
Pao, W.3
Hayday, A.4
Bolen, J.B.5
Pawson, T.6
-
22
-
-
0027420792
-
Cross-linking of Fc gamma receptor I (Fc gamma RI) and receptor II (Fc gamma RII) on monocytic cells activates a signal transduction pathway common to both Fc receptors that involves the stimulation of p72 Syk protein tyrosine kinase
-
Kiener PA, Rankin BM, Burkhardt AL, Schieven GL, Gilliland LK, Rowley RB, et al. Cross-linking of Fc gamma receptor I (Fc gamma RI) and receptor II (Fc gamma RII) on monocytic cells activates a signal transduction pathway common to both Fc receptors that involves the stimulation of p72 Syk protein tyrosine kinase. J Biol Chem. 1993;268(32):24442-8.
-
(1993)
J Biol Chem
, vol.268
, Issue.32
, pp. 24442-24448
-
-
Kiener, P.A.1
Rankin, B.M.2
Burkhardt, A.L.3
Schieven, G.L.4
Gilliland, L.K.5
Rowley, R.B.6
-
23
-
-
0028072499
-
Inhibition of mast cell Fc epsilon R1-mediated signaling and effector function by the Syk-selective inhibitor, piceatannol
-
Oliver JM, Burg DL, Wilson BS, McLaughlin JL, Geahlen RL. Inhibition of mast cell Fc epsilon R1-mediated signaling and effector function by the Syk-selective inhibitor, piceatannol. J Biol Chem. 1994;269(47):29697-703.
-
(1994)
J Biol Chem
, vol.269
, Issue.47
, pp. 29697-29703
-
-
Oliver, J.M.1
Burg, D.L.2
Wilson, B.S.3
McLaughlin, J.L.4
Geahlen, R.L.5
-
24
-
-
67649295511
-
Phosphoproteomic analysis of Syk kinase signaling in human cancer cells reveals its role in cell-cell adhesion
-
Larive RM, Urbach S, Poncet J, Jouin P, Mascre G, Sahuquet A, et al. Phosphoproteomic analysis of Syk kinase signaling in human cancer cells reveals its role in cell-cell adhesion. Oncogene. 2009;28(24):2337-47.
-
(2009)
Oncogene
, vol.28
, Issue.24
, pp. 2337-2347
-
-
Larive, R.M.1
Urbach, S.2
Poncet, J.3
Jouin, P.4
Mascre, G.5
Sahuquet, A.6
-
25
-
-
0034680108
-
The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells
-
Coopman PJ, Do MT, Barth M, Bowden ET, Hayes AJ, Basyuk E, et al. The Syk tyrosine kinase suppresses malignant growth of human breast cancer cells. Nature. 2000;406:742-7.
-
(2000)
Nature
, vol.406
, pp. 742-747
-
-
Coopman, P.J.1
Do, M.T.2
Barth, M.3
Bowden, E.T.4
Hayes, A.J.5
Basyuk, E.6
-
26
-
-
33746671852
-
The Syk tyrosine kinase: a new negative regulator in tumor growth and progression
-
Coopman PJ, Müller SC. The Syk tyrosine kinase: a new negative regulator in tumor growth and progression. Cancer Lett. 2006;241:159-73.
-
(2006)
Cancer Lett
, vol.241
, pp. 159-173
-
-
Coopman, P.J.1
Müller, S.C.2
-
27
-
-
63849309885
-
Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target
-
Young RM, Hardy IR, Clarke RL, Lundy N, Pine P, Turner BC, et al. Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. Blood. 2009;113(11):2508-16.
-
(2009)
Blood
, vol.113
, Issue.11
, pp. 2508-2516
-
-
Young, R.M.1
Hardy, I.R.2
Clarke, R.L.3
Lundy, N.4
Pine, P.5
Turner, B.C.6
-
28
-
-
70349284466
-
The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression
-
Baudot AD, Jeandel PY, Mouska X, Maurer U, Tartare-Deckert S, Raynaud SD, et al. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression. Oncogene. 2009;28(37):3261-73.
-
(2009)
Oncogene
, vol.28
, Issue.37
, pp. 3261-3273
-
-
Baudot, A.D.1
Jeandel, P.Y.2
Mouska, X.3
Maurer, U.4
Tartare-Deckert, S.5
Raynaud, S.D.6
-
29
-
-
77952886100
-
Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia
-
Buchner M, Baer C, Prinz G, Dierks C, Burger M, Zenz T, et al. Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia. Blood. 2010;115(22):4497-506.
-
(2010)
Blood
, vol.115
, Issue.22
, pp. 4497-4506
-
-
Buchner, M.1
Baer, C.2
Prinz, G.3
Dierks, C.4
Burger, M.5
Zenz, T.6
-
30
-
-
73849145729
-
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
-
Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277):88-92.
-
(2010)
Nature.
, vol.463
, Issue.7277
, pp. 88-92
-
-
Davis, R.E.1
Ngo, V.N.2
Lenz, G.3
Tolar, P.4
Young, R.M.5
Romesser, P.B.6
-
31
-
-
67650458526
-
Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia
-
Buchner M, Fuchs S, Prinz G, Pfeifer D, Bartholome K, Burger M, et al. Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia. Cancer Res. 2009;69(13):5424-32.
-
(2009)
Cancer Res
, vol.69
, Issue.13
, pp. 5424-5432
-
-
Buchner, M.1
Fuchs, S.2
Prinz, G.3
Pfeifer, D.4
Bartholome, K.5
Burger, M.6
-
32
-
-
41349110211
-
SYK-dependent tonic B cell receptor signaling is a rational treatment target in diffuse large B cell lymphoma
-
Chen L, Monti S, Juszczynski P, Daley J, Chen W, Witzig TE, et al. SYK-dependent tonic B cell receptor signaling is a rational treatment target in diffuse large B cell lymphoma. Blood. 2008;111(4):2230-7.
-
(2008)
Blood
, vol.111
, Issue.4
, pp. 2230-2237
-
-
Chen, L.1
Monti, S.2
Juszczynski, P.3
Daley, J.4
Chen, W.5
Witzig, T.E.6
-
33
-
-
34347215518
-
Analysis of apoptosis by propidium iodide staining and flow cytometry
-
Riccardi C, Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc. 2006;1(3):1458-61.
-
(2006)
Nat Protoc
, vol.1
, Issue.3
, pp. 1458-1461
-
-
Riccardi, C.1
Nicoletti, I.2
-
34
-
-
0041932075
-
The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents
-
Yamamoto N, Takeshita K, Shichijo M, Kokubo T, Sato M, Nakashima K, et al. The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents. J Pharmacol Exp Ther. 2003;306(3):1174-81.
-
(2003)
J Pharmacol Exp Ther
, vol.306
, Issue.3
, pp. 1174-1181
-
-
Yamamoto, N.1
Takeshita, K.2
Shichijo, M.3
Kokubo, T.4
Sato, M.5
Nakashima, K.6
-
35
-
-
80051779551
-
Fostamatinib, a Syk-kinase inhibitor, does not affect methotrexate pharmacokinetics in patients with rheumatoid arthritis
-
Baluom M, Samara E, Grossbard EB, Lau DT. Fostamatinib, a Syk-kinase inhibitor, does not affect methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Clin Pharmacol. 2011;51(9):1310-8.
-
(2011)
J Clin Pharmacol
, vol.51
, Issue.9
, pp. 1310-1318
-
-
Baluom, M.1
Samara, E.2
Grossbard, E.B.3
Lau, D.T.4
-
36
-
-
0036885057
-
Piceatannol inhibits TNF-induced NF-kappaB activation and NF-kappaB-mediated gene expression through suppression of IkappaBalpha kinase and p65 phosphorylation
-
Ashikawa K, Majumdar S, Banerjee S, Bharti AC, Shishodia S, Aggarwal BB. Piceatannol inhibits TNF-induced NF-kappaB activation and NF-kappaB-mediated gene expression through suppression of IkappaBalpha kinase and p65 phosphorylation. J Immunol. 2002;169(11):6490-7.
-
(2002)
J Immunol
, vol.169
, Issue.11
, pp. 6490-6497
-
-
Ashikawa, K.1
Majumdar, S.2
Banerjee, S.3
Bharti, A.C.4
Shishodia, S.5
Aggarwal, B.B.6
-
37
-
-
0035158357
-
Piceatannol, a hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary, leukemic lymphoblasts
-
Wieder T, Prokop A, Bagci B, Essmann F, Bernicke D, Schulze-Osthoff K, et al. Piceatannol, a hydroxylated analog of the chemopreventive agent resveratrol, is a potent inducer of apoptosis in the lymphoma cell line BJAB and in primary, leukemic lymphoblasts. Leukemia. 2001;15(11):1735-42.
-
(2001)
Leukemia
, vol.15
, Issue.11
, pp. 1735-1742
-
-
Wieder, T.1
Prokop, A.2
Bagci, B.3
Essmann, F.4
Bernicke, D.5
Schulze-Osthoff, K.6
-
38
-
-
70349237504
-
B cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406
-
Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda WG, et al. B cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406. Blood. 2009;114(5):1029-37.
-
(2009)
Blood
, vol.114
, Issue.5
, pp. 1029-1037
-
-
Quiroga, M.P.1
Balakrishnan, K.2
Kurtova, A.V.3
Sivina, M.4
Keating, M.J.5
Wierda, W.G.6
-
39
-
-
75749123824
-
Spleen tyrosine kinase: an Src family of non-receptor kinase has multiple functions and represents a valuable therapeutic target in the treatment of autoimmune and inflammatory diseases
-
Ghosh D, Tsokos GC. Spleen tyrosine kinase: an Src family of non-receptor kinase has multiple functions and represents a valuable therapeutic target in the treatment of autoimmune and inflammatory diseases. Autoimmunity. 2010;43(1):48-55.
-
(2010)
Autoimmunity
, vol.43
, Issue.1
, pp. 48-55
-
-
Ghosh, D.1
Tsokos, G.C.2
-
40
-
-
77957333252
-
An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis
-
Weinblatt ME, Kavanaugh A, Genovese MC, Musser TK, Grossbard EB, Magilavy DB. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med. 2010;363(14):1303-12.
-
(2010)
N Engl J Med
, vol.363
, Issue.14
, pp. 1303-1312
-
-
Weinblatt, M.E.1
Kavanaugh, A.2
Genovese, M.C.3
Musser, T.K.4
Grossbard, E.B.5
Magilavy, D.B.6
-
41
-
-
77951002653
-
Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
-
Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115(13):2578-85.
-
(2010)
Blood
, vol.115
, Issue.13
, pp. 2578-2585
-
-
Friedberg, J.W.1
Sharman, J.2
Sweetenham, J.3
Johnston, P.B.4
Vose, J.M.5
Lacasce, A.6
-
42
-
-
34249825194
-
Immunotoxicity assessment for the novel Spleen tyrosine kinase inhibitor R406
-
Zhu Y, Herlaar E, Masuda ES, Burleson GR, Nelson AJ, Grossbard EB, et al. Immunotoxicity assessment for the novel Spleen tyrosine kinase inhibitor R406. Toxicol Appl Pharmacol. 2007;221(3):268-77.
-
(2007)
Toxicol Appl Pharmacol
, vol.221
, Issue.3
, pp. 268-277
-
-
Zhu, Y.1
Herlaar, E.2
Masuda, E.S.3
Burleson, G.R.4
Nelson, A.J.5
Grossbard, E.B.6
-
43
-
-
0036681815
-
Chemotactic responsiveness toward ligands for CXCR3 and CXCR4 is regulated on plasma blasts during the time course of a memory immune response
-
Hauser AE, Debes GF, Arce S, Cassese G, Hamann A, Radbruch A, et al. Chemotactic responsiveness toward ligands for CXCR3 and CXCR4 is regulated on plasma blasts during the time course of a memory immune response. J Immunol. 2002;169(3):1277-82.
-
(2002)
J Immunol
, vol.169
, Issue.3
, pp. 1277-1282
-
-
Hauser, A.E.1
Debes, G.F.2
Arce, S.3
Cassese, G.4
Hamann, A.5
Radbruch, A.6
-
44
-
-
0037262287
-
Expression and function of chemokine receptors in human multiple myeloma
-
Moller C, Stromberg T, Juremalm M, Nilsson K, Nilsson G. Expression and function of chemokine receptors in human multiple myeloma. Leukemia. 2003;17(1):203-10.
-
(2003)
Leukemia
, vol.17
, Issue.1
, pp. 203-210
-
-
Moller, C.1
Stromberg, T.2
Juremalm, M.3
Nilsson, K.4
Nilsson, G.5
-
45
-
-
34547106018
-
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets
-
Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007;7(8):585-98.
-
(2007)
Nat Rev Cancer
, vol.7
, Issue.8
, pp. 585-598
-
-
Hideshima, T.1
Mitsiades, C.2
Tonon, G.3
Richardson, P.G.4
Anderson, K.C.5
-
46
-
-
0035880256
-
Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration
-
Podar K, Tai YT, Davies FE, Lentzsch S, Sattler M, Hideshima T, et al. Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. Blood. 2001;98(2):428-35.
-
(2001)
Blood
, vol.98
, Issue.2
, pp. 428-435
-
-
Podar, K.1
Tai, Y.T.2
Davies, F.E.3
Lentzsch, S.4
Sattler, M.5
Hideshima, T.6
-
47
-
-
84867337239
-
(Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials
-
Wang A, Duan Q, Liu X, Ding K, Han Y, Zhu W, et al. (Bortezomib plus lenalidomide/thalidomide)- vs. (bortezomib or lenalidomide/thalidomide)-containing regimens as induction therapy in newly diagnosed multiple myeloma: a meta-analysis of randomized controlled trials. Ann Hematol. 2012;91(11):1779-84.
-
(2012)
Ann Hematol.
, vol.91
, Issue.11
, pp. 1779-1784
-
-
Wang, A.1
Duan, Q.2
Liu, X.3
Ding, K.4
Han, Y.5
Zhu, W.6
-
48
-
-
84865606568
-
The application and biology of immunomodulatory drugs (IMiDs) in cancer
-
Pan B, Lentzsch S. The application and biology of immunomodulatory drugs (IMiDs) in cancer. Pharmacol Ther. 2012;136(1):56-68.
-
(2012)
Pharmacol Ther.
, vol.136
, Issue.1
, pp. 56-68
-
-
Pan, B.1
Lentzsch, S.2
-
49
-
-
67650995912
-
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235
-
McMillin DW, Ooi M, Delmore J, Negri J, Hayden P, Mitsiades N, et al. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res. 2009;69(14):5835-42.
-
(2009)
Cancer Res
, vol.69
, Issue.14
, pp. 5835-5842
-
-
McMillin, D.W.1
Ooi, M.2
Delmore, J.3
Negri, J.4
Hayden, P.5
Mitsiades, N.6
|